http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013510878-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-133 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013510878-A |
| titleOfInvention | Compositions and methods for treating hyperproliferative disorders |
| abstract | A method of treating a hyperproliferative disorder in a subject in need of treatment for a hyperproliferative disorder, comprising: treating the subject with a therapeutically effective amount of (a) a ceramide-enhancing retinoid such as fenretinide (fenretinide) An acceptable salt; and (b) at least one (and in certain embodiments, at least two) compounds, comprising: (i) one or more non-18 carbon chain lengths of L-threo-sphinganine or them A pharmaceutically acceptable salt of (ii) one or more glucosylceramides or glucosyl (dihydro) ceramide synthesis inhibitors, and (iii) one or more sphingomyelin or dihydrosphingomyelin synthase inhibitors Administering a combination of more selected compounds. Preferred L-threo-sphinganins have a carbon chain length of 17 carbons, 19 carbons or 20 carbons. A preferred glucosylceramide or glucosyl (dihydro) ceramide synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingomyelin or dihydrosphingomyelin synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred hyperproliferative disorder is brain cancer. [Selection] Figure 1 |
| priorityDate | 2009-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 163.